Wells Fargo & Company Vista Gen Therapeutics, Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.12 - $0.3 $4,688 - $11,720	39,067 Added 38.11%	141,567 $16,000
Q4 2022 Feb 13, 2023	BUY	$0.09 - $0.16 $2,277 - $4,049	25,309 Added 32.79%	102,500 $10,000
Q3 2022 Nov 14, 2022	SELL	$0.14 - $1.07 $333 - $2,548	-2,382 Reduced 2.99%	77,191 $11,000
Q2 2022 Aug 12, 2022	SELL	$0.88 - $1.73 $33,497 - $65,852	-38,065 Reduced 32.36%	79,573 $70,000
Q1 2022 May 16, 2022	SELL	$1.14 - $2.09 $74,183 - $136,002	-65,073 Reduced 35.62%	117,638 $145,000

Q4 2021 Feb 14, 2022	BUY	$1.67 - $2.76 $161,584 - $267,049	96,757 Added 112.57%	182,711 $356,000
Q3 2021 Nov 15, 2021	BUY	$2.62 - $3.45 $225,199 - $296,541	85,954 New	85,954 $235,000
Q2 2021 Aug 16, 2021	SELL	$1.96 - $3.15 $1,691 - $2,718	-863 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$1.89 - $2.96 $835 - $1,308	442 Added 104.99%	863 $2,000
Q3 2020 Nov 05, 2020	BUY	$0.48 - $1.03 $58 - $124	121 Added 40.33%	421 $0
Q2 2020 Aug 13, 2020	BUY	$0.37 - $0.61 $0 - $1	2 Added 0.67%	300 $0
Q1 2020 May 14, 2020	BUY	$0.32 - $0.8 $95 - $238	298 New	298 $0

2.7M

Ticker VTGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 206,836,000
Market Cap $720M
Description
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III d...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.